Up-to-date access to technology licensing opportunities worldwide.
Displaying 1..3 of 3 -
per page
Order by
NCEs for innovative therapeutic targets in inflammatory/immunologic diseases.
More
Phase III and beyond prescription products are sought to in-license into the four major Nordic countries.
More
Leiras Finland is looking to in-license new prescription products for the Nordic region including Finland, Sweden, Norway and Denmark.
More
Displaying 1..3 of 3 -
per page
Order by
Aug 2008 - 120 pages - $1,040
May 2011 - 43 pages - $500
Nov 2010 - 40 pages - $500
Sep 2010 - 412 pages - $1,040
Nov 2010 - 7 pages - $500
Jan 2006 - 1126 pages - $2,495
Nov 2010 - 102 pages - $1,495
Nov 2010 - 117 pages - $1,495